APS.TO Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 21:59):

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States...

Stats
Dagens volum	34 400.00
Gjennomsnittsvolum	8 958.00
Markedsverdi	26.72M
EPS	$0 ( 2024-03-26 )
Neste inntjeningsdato	( $-1.010 ) 2024-05-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.160
ATR14	$0.0260 (1.53%)

Aptose Biosciences Inc Korrelasjon

10 Mest positive korrelasjoner
IVQ.TO	0.87
ME.TO	0.86
IVX.V	0.86
AH.TO	0.859
PYR.TO	0.859
NBVA.V	0.851
GKO.V	0.851
PLRB.V	0.847
LGD.TO	0.842
GBT.TO	0.838

10 Mest negative korrelasjoner
APL.V	-0.878
MAGT.TO	-0.872
SNC.TO	-0.865
URB.TO	-0.862
MCB.TO	-0.86
WE.V	-0.851
HSAV.TO	-0.849
SJR-B.TO	-0.848
HURA.TO	-0.847
DRX.TO	-0.844

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Aptose Biosciences Inc Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-7.58

FY	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-7.58

FY	2022
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-0.440

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.730

Financial Reports:

No articles found.

Aptose Biosciences Inc

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.